It says something about the current reputation of the pharmaceutical industry that the toughest questions during the Nov. 29 Senate Health Committee hearing on the nomination of Alex Azar to be HHS Secretary came from the members of the panel who are at opposite ends of the ideological spectrum: Sen. Elizabeth Warren (D-MA) and Sen. Rand Paul (R-KY).
Warren and Paul don’t agree on much. But they both agreed during the hearing that Azar’s background as an executive...